NCT00004431CompletedNot Applicable
Randomized Study of L-Baclofen in Patients With Refractory Trigeminal Neuralgia
Conditions
Drugs
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- University of Pittsburgh
- Enrollment
- 30
- Locations
- 1
Study Overview
Brief Summary
OBJECTIVES: I. Evaluate the efficacy of L-baclofen in patients with refractory trigeminal neuralgia.
II. Evaluate the safety and tolerance of L-baclofen in these patients.
Detailed Description
PROTOCOL OUTLINE: This is a randomized, double blind, placebo controlled, parallel study.
Patients are randomized to receive either L-baclofen or placebo orally at increasing daily doses for 1 week. Patients then continue to receive the maximum dosage acceptable for a 1 week maintenance period.
Patients, thereafter, may enroll in a long term open label study with L-baclofen.
Patients are followed at 1, 3, 6, 9, and 12 months.
Completion date provided represents the completion date of the grant per OOPD records
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Double
Eligibility Criteria
- Ages
- 18 Years to 80 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •PROTOCOL ENTRY CRITERIA:
- •-Disease Characteristics-- Idiopathic trigeminal neuralgia - Paroxysmal attacks of facial or frontal pain lasting a few seconds to less than 2 minutes - Pain has at least 4 of the following characteristics: Distribution along one or more divisions of the trigeminal nerve Sudden, intense, sharp, superficial, stabbing, or burning quality Pain intensity severe Precipitation from trigger areas, or by certain daily activities such as eating, talking, washing the face, or cleaning the teeth Between paroxysms entirely asymptomatic - No neurological deficit - Attacks are stereotyped in the individual patient - Exclusion of other causes of facial pain by history, physical examination and special investigations when necessary Must be uncontrolled or refractory as defined by occurrence of at least 2 paroxysms of pain per day despite conventional treatment with maximally tolerated doses of carbamazepine --Prior/Concurrent Therapy-- No concurrent medication for trigeminal neuralgia other than carbamazepine, phenytoin, and neurontin Concurrent medication for other conditions allowed Concurrent medication must be on stable dose(s) --Patient Characteristics-- Hepatic: No significant hepatic disease Renal: No significant renal disease Neurological: No evidence of progressing neurological disorder (e.g., intracranial neoplasm, multiple sclerosis) Other: No history of drug abuse Not pregnant Effective contraception required of all fertile patients
Exclusion Criteria
- Not provided
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Not Applicable
Observational Study on Patients With Baclofen Treatment for Alcohol-dependence in FranceAlcohol DrinkingAlcohol WithdrawalCirrhosisNCT02835365Centre Hospitalier Intercommunal Creteil218
Completed
Phase 3
Dutch National ITB Study in Children With Cerebral PalsySpasticityCerebral PalsyNCT00367068Maastricht University18
Withdrawn
Not Applicable
Open Label Treatment of Severe Tactile Defensiveness With Intrathecal BaclofenAutism Spectrum DisorderNCT01352611University of Missouri-Columbia
Active, not recruiting
Not Applicable
A placebo controlled trial with Baclofen for the treatment of GERD patients with incomplete PPI responseGastroesophageal reflux diseaseEUCTR2009-017351-96-BEZleuven
Active, not recruiting
Phase 1
Study investigating the effect of baclofen in patients with postprandial regurgitation or belchingMedDRA version: 14.0Level: LLTClassification code 10004222Term: BelchingSystem Organ Class: 10017947 - Gastrointestinal disordersRumination syndrome and supragastric belchingMedDRA version: 14.0Level: LLTClassification code 10039292Term: Rumination disorderSystem Organ Class: 10037175 - Psychiatric disordersEUCTR2011-002745-35-BEZLeuven20